<p>Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ:<a class="ticker" ...

<p>Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ISPC">ISPC</a>) a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order.</p><p>The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coordinated the sourcing and collection of the required specimens and managed international fulfillment to meet the project's timeline.</p><p>iSpecimen maintains a global and domestic network of healthcare institutions, laboratories, biobanks, and research partners that supports the sourcing of specialized cancer specimens, including formalin-fixed, paraffin-embedded (FFPE) and flash-frozen tissue.</p><p>The successful completion of the project reflects iSpecimen's focus on efficient biospecimen sourcing and fulfillment in response to a large, time-sensitive research request. Ms. Field, iSpecimen's Chief Executive Officer, commented: "Every week a researcher spends waiting on specimens is a week that discovery is on hold. Delivering hundreds of cancer specimens internationally within three weeks of receiving the purchase order reflects the network we've built and the team that runs it&#160;&#8212; and it can help our customers keep their research moving."</p><p>About iSpecimen Inc.</p><p>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ISPC">ISPC</a>) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit <a href="https://api.newsfilecorp.com/redirect/WAoENcnj4w">www.ispecimen.com</a>.</p><p>Forward-Looking Statements</p><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding iSpecimen's expectations, plans, and future prospects and are generally identified by words such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "continue," "could," "should," "plan," "potential," or similar expressions. These statements are based on iSpecimen's current expectations and assumptions and are not guarantees of future performance.</p><p>Actual results and events may differ materially from those expressed or implied by the forward-looking statements in this press release due to risks and uncertainties, including, without limitation, risks relating to iSpecimen's ability to source, collect, ship, and fulfill biospecimen orders; the timing, scope, and requirements of customer projects; reliance on healthcare and research partners; international shipping and applicable legal and regulatory requirements; and other risk factors described in iSpecimen's filings with the SEC, which are available for review at <a href="https://api.newsfilecorp.com/redirect/qp5wWfM27y">www.sec.gov</a>. These risks and uncertainties are not exhaustive. New risks and uncertainties may arise from time to time, and it is not possible for iSpecimen to predict all such risks or their impact. If any of the events or circumstances reflected in iSpecimen's forward-looking statements occur, iSpecimen's business, financial condition, and operating results may vary materially from those expressed or implied in those statements.</p><p>Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable law, iSpecimen assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.</p><div id="contactInfo"><p>For further information, please contact:</p><p><a href="mailto:info@ispecimen.com">info@ispecimen.com</a></p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10995/310636_412a3622645858a5_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/nomEYTjOKX">https://www.newsfilecorp.com/release/310636</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/310636/197" alt="" /></p>

ISPC

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

iSpecimen completes large international cancer biospecimen project, signaling scalable network

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p&gt;Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ:&lt;a class=&quot;ticker&quot; ...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>iSpecimen announced the completion of an international cancer biospecimen project involving hundreds of samples, with shipments within three weeks of the purchase order. The effort highlights its global network and rapid fulfillment, potentially accelerating future project opportunities as researchers demand time-sensitive access. While forward-looking statements carry caution, execution may improve revenue visibility if repeat contracts arise.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>iSpecimen completed an international cancer biospecimen project; samples shipped within three weeks.</li><li>Project coordinated large-scale sourcing; demonstrates efficient fulfillment network.</li><li>CEO Field notes speed reduces discovery time; potential customer pull.</li><li>No revenue figures provided; forward-looking statements caution.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>iSpecimen (ISPC)</strong>: Primary beneficiary of the release; showcases rapid fulfillment and broad partner network.</li><li><strong>None (N/A)</strong>: No additional public-company mentions beyond iSpecimen in the press release.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News; confirms a real-world, large-scale project execution in biospecimen sourcing, reinforcing iSpecimen&#039;s competitive moat and potential demand sellers. The focus on speed and network breadth supports ISPC&#039;s positioning but lacks immediate revenue data.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Time-sensitive project validates iSpecimen&#039;s scalable biospecimen sourcing network.</li><li>Potential for follow-on orders could lift near-term revenue visibility.</li><li>No revenue figures disclosed; market reaction hinges on subsequent contract detail.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Project involved hundreds of cancer blood specimens.</li><li>Samples shipped within three weeks of receiving the purchase order.</li><li>Announcement date: August 20, 2026.</li><li>Specimens include FFPE and flash-frozen tissue.</li><li>Company: iSpecimen Inc., NASDAQ ISPC.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Positive execution could unlock incremental project wins; near-term upside visible within weeks.</p>
  </section>
</section>


<article>
  <header>
    <h2>ISPC Reports Completion of Large-Scale International Cancer Research Order; Hundreds of Samples Shipped Within Three Weeks</h2>
  </header>

  <section aria-label="Executive Summary">
    <p><strong>Woburn, Massachusetts</strong>—(Newsfile Corp. - August 20, 2026) iSpecimen, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ISPC">ISPC</a>) a provider of human biospecimens, recently completed an international cancer research project involving <strong>hundreds of cancer blood specimens</strong>, with the samples shipped within <strong>three weeks</strong> of receiving the purchase order. This milestone underscores ISPC's ability to source and fulfill time-sensitive biospecimen orders through a global partner network.</p>
  </section>

  <section aria-label="Project Scope and Timeline">
    <h3>Project scope and execution</h3>
    <p>The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coordinated the sourcing and collection of the required specimens and managed international fulfillment to meet the project's timeline.</p>

    <p>ISPC maintains a global and domestic network of healthcare institutions, laboratories, biobanks, and research partners that supports the sourcing of specialized cancer specimens, including formalin-fixed, paraffin-embedded (FFPE) and flash-frozen tissue.</p>

    <blockquote>“Every week a researcher spends waiting on specimens is a week that discovery is on hold. Delivering hundreds of cancer specimens internationally within three weeks of receiving the purchase order reflects the network we've built and the team that runs it&#160;&#8212; and it can help our customers keep their research moving.”</blockquote>
  </section>

  <section aria-label="About iSpecimen and ISPC">
    <h3>Company background and ISPC stock information</h3>
    <p>About iSpecimen Inc. (<strong>NASDAQ:</strong><a class="ticker" href="https://www.benzinga.com/quote/ISPC">ISPC</a>) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit <a href="https://api.newsfilecorp.com/redirect/WAoENcnj4w">www.ispecimen.com</a>.</p>
  </section>

  <section aria-label="Forward-Looking Statements">
    <h3>Forward-Looking Statements</h3>
    <p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding iSpecimen's expectations, plans, and future prospects and are generally identified by words such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "continue," "could," "should," "plan," "potential," or similar expressions. These statements are based on iSpecimen's current expectations and assumptions and are not guarantees of future performance.</p>

    <p>Actual results and events may differ materially from those expressed or implied by the forward-looking statements in this press release due to risks and uncertainties, including, without limitation, risks relating to iSpecimen's ability to source, collect, ship, and fulfill biospecimen orders; the timing, scope, and requirements of customer projects; reliance on healthcare and research partners; international shipping and applicable legal and regulatory requirements; and other risk factors described in iSpecimen's filings with the SEC, which are available for review at <a href="https://api.newsfilecorp.com/redirect/qp5wWfM27y">www.sec.gov</a>. These risks and uncertainties are not exhaustive. New risks and uncertainties may arise from time to time, and it is not possible for iSpecimen to predict all such risks or their impact. If any of the events or circumstances reflected in iSpecimen's forward-looking statements occur, iSpecimen's business, financial condition, and operating results may vary materially from those expressed or implied in those statements.</p>

    <p>Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable law, iSpecimen assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
  </section>

  <section aria-label="Key Facts">
    <h3>Key facts and figures</h3>
    <ul>
      <li><strong>Hundreds of cancer blood specimens</strong> were involved in the international project.</li>
      <li>The samples were shipped <strong>within three weeks</strong> of receiving the purchase order.</li>
      <li>ISPC maintains a <strong>global and domestic network</strong> of healthcare institutions, laboratories, biobanks, and research partners to source specialized cancer specimens, including <em>FFPE</em> and <em>flash-frozen tissue</em>.</li>
    </ul>
  </section>

  <section aria-label="Contact Information">
    <h3>Contact information</h3>
    <p>For further information, please contact: <a href="mailto:info@ispecimen.com">info@ispecimen.com</a></p>
  </section>
</article>

iSpecimen announced the completion of an international cancer biospecimen project involving hundreds of samples, with shipments within three weeks of the purchase order. The effort highlights its global network and rapid fulfillment, potentially accelerating future project opportunities as researchers demand time-sensitive access. While forward-looking statements carry caution, execution may improve revenue visibility if repeat contracts arise.

News insight

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

AI summary

Sentiment rationale

Key facts

Industry News